A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
The purpose of this trial is to determine if pharmacogenetically targeted bucindolol is superior to Toprol-XL for reducing the recurrence of symptomatic atrial fibrillation/atrial flutter (AF/AFL) in a genotype-defined population with heart failure and/or reduced left ventricular ejection fraction (LVEF) and persistent symptomatic AF requiring electrical cardioversion to sinus rhythm.
GENETIC-AF is a double-blind, two-arm, genotype-directed, active-controlled, adaptive-design, superiority study.
Time to first event of symptomatic atrial fibrillation/atrial flutter (AF/AFL) or all-cause mortality (ACM) during the 24-week follow-up period after conversion to stable sinus rhythm.
ARCA biopharma Inc